Coherus BioSciences develops immuno-oncology therapies aimed at cancer treatment, including FDA-approved medicines such as LOQTORZI. It focuses on improving patient outcomes through a diversified pipeline of drug candidates.

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

COM:COHERUS

Coherus BioSciences

Last Close

1.10

22/11 17:58

Market Cap

127.31M

Beta: -

Volume Today

1.54M

Avg: -

locale

market

industry

website

ipo date

competitor of

Metrics